Related Experiment Videos
Stroke: therapeutic approaches
1Eli Lilly and Co. Ltd., Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, UK.
Drug News & Perspectives
|December 24, 2004
Summary
Drug development for stroke faces challenges, particularly in late-stage trials. Careful examination of side effect profiles, pharmacokinetics, and distribution is crucial to minimize cardiovascular risks.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Stroke remains a leading cause of disability and death.
- Many promising stroke therapies fail during late-stage clinical trials.
- Understanding reasons for drug failure is critical for advancing stroke treatment.
Purpose of the Study:
- To review challenges in stroke drug development.
- To discuss in vitro and in vivo models of ischemia.
- To explore therapeutic approaches for stroke.
Main Methods:
- Symposium presentation and discussion.
- Review of late-stage clinical trial failures.
- Analysis of ischemia models.
- Evaluation of therapeutic strategies.
Main Results:
- Drug development failures are multifactorial.
- In vitro and in vivo models aid research but have limitations.
- Cardiovascular side effects are a significant concern in stroke drug trials.
Conclusions:
- Thorough evaluation of side effect profiles is essential.
- Pharmacokinetics and drug distribution require close examination.
- Minimizing cardiovascular effects is key to successful stroke drug development.